Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
5.38
-0.25 (-4.44%)
Aug 1, 2025, 4:00 PM - Market closed
Pulmatrix Revenue
Pulmatrix had revenue of $1.92M in the twelve months ending March 31, 2025, down -83.56% year-over-year. In the year 2024, Pulmatrix had annual revenue of $7.81M with 6.96% growth.
Revenue (ttm)
$1.92M
Revenue Growth
-83.56%
P/S Ratio
10.14
Revenue / Employee
$960,500
Employees
2
Market Cap
19.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.81M | 508.00K | 6.96% |
Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PULM News
- 2 months ago - Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - PRNewsWire
- 3 months ago - PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM - Business Wire
- 4 months ago - Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - PRNewsWire
- 9 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 9 months ago - Pulmatrix and Cullgen Announce Proposed Merger - PRNewsWire
- 9 months ago - Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 1 year ago - Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 1 year ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire